Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Assets: 2010-2024

Historic Assets for Ani Pharmaceuticals (ANIP) over the last 15 years, with Dec 2024 value amounting to $1.3 billion.

  • Ani Pharmaceuticals' Assets rose 9.38% to $1.4 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.4 billion, marking a year-over-year increase of 9.38%. This contributed to the annual value of $1.3 billion for FY2024, which is 41.94% up from last year.
  • As of FY2024, Ani Pharmaceuticals' Assets stood at $1.3 billion, which was up 41.94% from $904.4 million recorded in FY2023.
  • Ani Pharmaceuticals' Assets' 5-year high stood at $1.3 billion during FY2024, with a 5-year trough of $461.2 million in FY2020.
  • Over the past 3 years, Ani Pharmaceuticals' median Assets value was $904.4 million (recorded in 2023), while the average stood at $982.7 million.
  • In the last 5 years, Ani Pharmaceuticals' Assets skyrocketed by 67.31% in 2021 and then dropped by 1.49% in 2022.
  • Yearly analysis of 5 years shows Ani Pharmaceuticals' Assets stood at $461.2 million in 2020, then spiked by 67.31% to $771.6 million in 2021, then dropped by 1.49% to $760.1 million in 2022, then increased by 18.99% to $904.4 million in 2023, then surged by 41.94% to $1.3 billion in 2024.